Search

Your search keyword '"Altcheh, Jaime"' showing total 343 results
Start Over Author "Altcheh, Jaime"
343 results on '"Altcheh, Jaime"'

4. Congenital Chagas Disease

Author

Altcheh, Jaime Marcelo, Kaufmann, Stefan H.E., Section Editor, Weber, Olaf, Series Editor, Altcheh, Jaime Marcelo, editor, and Freilij, Hector, editor

Published
2019
Full Text
View/download PDF

9. Clinical use of molecular methods for Trypanosoma cruzi infection in endemic and non-endemic countries: Benefits, limitations and challenges

Author

Pinazo, Maria-Jesus, primary, Forsyth, Colin J., additional, Lopez-Albizu, Constanza, additional, Bisio, Margarita María Catalina, additional, González-Martínez, Adriana, additional, Bohorquez, Laura, additional, Pinto, Jimy, additional, Molina, Israel, additional, Marchiol, Andrea, additional, Herazo, Rafael, additional, Galván, Irene Losada, additional, Marques, Tayná, additional, Barreira, Fabiana, additional, Villar, Juan Carlos, additional, Sguassero, Yanina, additional, Santini, Maria Soledad, additional, Altcheh, Jaime, additional, Alarcón de Noya, Belkisyolé, additional, and Sosa-Estani, Sergio, additional

Published
2023
Full Text
View/download PDF

10. Deep serological profiling of the Trypanosoma cruzi TSSA antigen reveals different epitopes and modes of recognition by Chagas disease patients

Author

Romer, Guadalupe, primary, Bracco, Leonel A., additional, Ricci, Alejandro D., additional, Balouz, Virginia, additional, Berná, Luisa, additional, Villar, Juan C., additional, Ramsey, Janine M., additional, Nolan, Melissa S., additional, Torrico, Faustino, additional, Kesper, Norival, additional, Altcheh, Jaime, additional, Robello, Carlos, additional, Buscaglia, Carlos A., additional, and Agüero, Fernán, additional

Published
2023
Full Text
View/download PDF

11. Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation

Author

Altcheh, Jaime, primary, Moscatelli, Guillermo, additional, Caruso, Martin, additional, Moroni, Samanta, additional, Bisio, Margarita, additional, Miranda, Maria Rosa, additional, Monla, Celia, additional, Vaina, Maria, additional, Valdez, Maria, additional, Moran, Lucrecia, additional, Ramirez, Teresa, additional, Patiño, Oscar Ledesma, additional, Riarte, Adelina, additional, Gonzalez, Nicolas, additional, Fernandes, Jayme, additional, Alves, Fabiana, additional, Ribeiro, Isabela, additional, and Garcia-Bournissen, Facundo, additional

Published
2023
Full Text
View/download PDF

16. Electrochemical magnetic microbeads-based biosensor for point-of-care serodiagnosis of infectious diseases

Author

Cortina, María E., Melli, Luciano J., Roberti, Mariano, Mass, Mijal, Longinotti, Gloria, Tropea, Salvador, Lloret, Paulina, Serantes, Diego A. Rey, Salomón, Francisco, Lloret, Matías, Caillava, Ana J., Restuccia, Sabrina, Altcheh, Jaime, Buscaglia, Carlos A., Malatto, Laura, Ugalde, Juan E., Fraigi, Liliana, Moina, Carlos, Ybarra, Gabriel, Ciocchini, Andrés E., and Comerci, Diego J.

Published
2016
Full Text
View/download PDF

18. Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study

Author

González, Nicolás Leonel, primary, Moscatelli, Guillermo, additional, Moroni, Samanta, additional, Ballering, Griselda, additional, Jurado, Laura, additional, Falk, Nicolás, additional, Bochoeyer, Andrés, additional, Goldsman, Alejandro, additional, Grippo, María, additional, Freilij, Héctor, additional, Garcia Bournissen, Facundo, additional, Chatelain, Eric, additional, and Altcheh, Jaime, additional

Published
2022
Full Text
View/download PDF

19. Multilocus sequence typing of Treponema pallidum pallidum in children with acquired syphilis by nonsexual contact

Author

Garcia, Luciana N, primary, Morando, Nicolás, additional, Otero, Adrián V, additional, Moroni, Samanta, additional, Moscatelli, Guillermo F, additional, Gonzalez, Nicolás, additional, D Slojan, Alejandra, additional, Lascano, Fernanda, additional, Ballering, Griselda, additional, Pando, Maria A, additional, and Altcheh, Jaime M, additional

Published
2022
Full Text
View/download PDF

20. POPULATION PHARMACOKINETICS OF BENZNIDAZOLE IN NEONATES, INFANTS AND CHILDREN USING A NEW PEDIATRIC FORMULATION

Author

Altcheh, Jaime, primary, Moscatelli, Guillermo, additional, Caruso, Martin, additional, Moroni, Samanta, additional, Bisio, Margarita, additional, Miranda, Maria Rosa, additional, Monla, Celia, additional, Vaina, Maria, additional, Valdez, Maria, additional, Moran, Lucrecia, additional, Ramirez, Teresa, additional, Patiño, Oscar Ledesma, additional, Riarte, Adelina, additional, Gonzalez, Nicolas, additional, Fernandes, Jayme, additional, Alves, Fabiana, additional, Ribeiro, Isabela, additional, and Garcia-Bournissen, Facundo, additional

Published
2022
Full Text
View/download PDF

21. Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis

Author

Altcheh, Jaime, primary, Carosella, Mabel V., additional, Ceballos, Ana, additional, D’Andrea, Ulises, additional, Jofre, Sandra M., additional, Marotta, Carolina, additional, Mugeri, Domingo, additional, Sabbaj, Liliana, additional, Soto, Adriana, additional, Josse, Constant, additional, Montestruc, Francois, additional, and McFarland, Lynne V., additional

Published
2022
Full Text
View/download PDF

22. A Trypanosoma cruzi Antigen and Epitope Atlas: deep characterization of antibody specificities in Chagas Disease patients across the Americas

Author

Ricci, Alejandro D., primary, Bracco, Leonel, additional, Ramsey, Janine M., additional, Nolan, Melissa S., additional, Lynn, M. Katie, additional, Altcheh, Jaime, additional, Ballering, Griselda, additional, Torrico, Faustino, additional, Kesper, Norival, additional, Villar, Juan C., additional, Marco, Jorge D., additional, and Agüero, Fernán, additional

Published
2022
Full Text
View/download PDF

25. ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.

Author

Rivero, Rocio, Esteva, Mónica Inés, Huang, Erya, Colmegna, Leylen, Altcheh, Jaime, Grossmann, Ulrike, and Ruiz, Andrés Mariano

Subjects
CHAGAS' disease, CHILD patients, HIV seroconversion, TREATMENT effectiveness, ENZYME-linked immunosorbent assay, PARASITIC diseases
Abstract

Background: Measurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects of nifurtimox administered by two different treatment regimens on the T. cruzi calcium-binding flagellar protein F29 in children diagnosed with Chagas disease measured using an enzyme-linked immunosorbent assay (ELISA) technique (ELISA F29). Methods and principal findings: In a phase 3, randomized, double-blind, parallel-group, historically controlled study (ClinicalTrials.gov NCT02625974), blood samples obtained from children diagnosed with Chagas disease and treated with nifurtimox for either 60 days or 30 days were analyzed using an ELISA with an F29 recombinant protein as the antigen, as well as conventional serological tests (recombinant ELISA and indirect hemagglutination assay). In an exploratory approach, serological response to nifurtimox treatment was evaluated for 4 years post-treatment. In both treatment groups, the number of patients with negative ELISA F29 values increased over the period of observation. The incidence rate of negative seroconversion using ELISA F29 was 22.94% (95% CI: 19.65%, 26.63%) in the 60-day treatment group and 21.64% (95% CI: 17.21%, 26.86%) in the 30-day treatment group. In the subpopulation of patients who tested seropositive for F29 before nifurtimox treatment, 88 patients (67.7%) in the 60-day regimen and 39 patients (59.1%) in the 30-day regimen were F29 seronegative at 4 years post-treatment. All patients who had a positive ELISA F29 test at baseline and seroconverted to negative measured by conventional serology reached seronegativity in ELISA F29 earlier than in conventional serology. Conclusions: The results demonstrate a serological response to treatment with nifurtimox measured by the ELISA F29 test in children diagnosed with Chagas disease. The F29-based ELISA can be considered a potential early marker of response to antitrypanosomal therapy for Chagas disease. Trial registration: ClinicalTrials.gov NCT02625974. Author summary: Chagas disease (American trypanosomiasis) is a potentially life-threatening parasitic disease caused by Trypanosoma cruzi. Measurement of the success of antitrypanosomal treatment is difficult, particularly in the chronic phase of the disease, because serum anti-T. cruzi antibodies persist for prolonged periods even after complete elimination of the parasite. Thus, markers for early assessment of response to antitrypanosomal therapy could be useful tools to monitor response to drug treatment in Chagas disease. In this prospective study, we analyzed serum samples obtained from children diagnosed with Chagas disease and treated with nifurtimox (an antitrypanosomal drug with proven effectiveness). Before treatment and at each annual visit for the 4 years after treatment, we measured levels of antibodies to a specific antigenic protein (F29) of T. cruzi parasite using an established immunological technique; enzyme-linked immunosorbent assay (ELISA). The number of patients with negative ELISA F29 results increased over the period of observation after the end of treatment. At 4 years post-treatment, we found seronegative ELISA F29 test results in 67.7% of the patients in the 60-day nifurtimox regimen and in 59.1% of the patients in the 30-day nifurtimox regimen. The F29-based ELISA can be considered a useful method to monitor responses to drug treatment in children with asymptomatic Chagas disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Development of a Method for Identification and Quantification of Sulfadiazine and Pyrimethamine in Serum of Congenital Toxoplasmosis Pediatric Patients

Author

Altcheh Jaime, Pérez Montilla Carlos, Mastrantonio Guido, Moroni Samanta, Maria Elena Marson, Fleitas Ulises, Prospitti Anabela, Moscatelli Guillermo, and García Bournissen Facundo

Subjects
Detection limit, Chromatography, biology, medicine.diagnostic_test, business.industry, Toxoplasma gondii, biology.organism_classification, medicine.disease, High-performance liquid chromatography, Toxoplasmosis, Pyrimethamine, Sulfadiazine, Therapeutic drug monitoring, medicine, business, Pediatric pharmacology, medicine.drug
Abstract

Infection with Toxoplasma gondii, is one of the most widespread zoonoses in the world. Congenital Toxoplasmosis (CT) is particularly risky due to its fetal complications. Sulfadiazine (SDZ) and Pyrimethamine (PYR) are usually used for CT treatment in Argentina, to prevent morbidity. Due to the lack of commercial pediatric formulations, these must be prepared in the hospital pharmacy. This is the first report of serum concentrations measures in pediatric CT therapy for this combination of drugs. A bioanalytical method was developed for identification and simultaneous quantification of SDZ and PYR by High Performance Liquid Chromatography (HPLC) with UV detection. The validated method was applied to residual serum samples obtained from 6 pediatric patients undergoing treatment with SDZ 42.20 a 93.70 mg/kg/day and PYR 0.77 a 2.70 mg/kg/day. Sample pretreatment consisted on a deproteinization step followed by centrifugation and then injection of supernatant. Limit of Detection (LOD) and Quantification (LOQ) were (0.17 ± 0.02 and 0.13 ± 0.02) μg/mL and (0.46 ± 0.01 and 0.36 ± 0.01) μg/mL for SDZ and PYR respectively, with an appropriate linear range. Concentrations range found were ( - 162.04 ± 0.02) μg/mL for SDZ and ( - 7.30 ± 0.03) μg/mL for PYR. We developed and validated in real pediatric samples, an acute, precise and low-cost method for quantification of SDZ and PYR using a non-sophisticate chromatographic equipment, suitable for hospital therapeutic monitoring for public health system.

Published
2021

29. Evaluation of the Chagas Western Blot IgG Assay for the Diagnosis of Chagas Disease

Author

Brossas, Jean-Yves, primary, Griselda, Ballering, additional, Bisio, Margarita, additional, Guihenneuc, Jeremy, additional, Gulin, Julián Ernesto Nicolás, additional, Jauréguiberry, Stéphane, additional, Lescure, François-Xavier, additional, Fekkar, Arnaud, additional, Mazier, Dominique, additional, Altcheh, Jaime, additional, and Paris, Luc, additional

Published
2021
Full Text
View/download PDF

31. Development of a Method for Identification and Quantification of Sulfadiazine and Pyrimethamine in Serum of Congenital Toxoplasmosis Patients

Author

Fleitas Ulises, Moroni Samanta, Altcheh Jaime, García Bournissen Facundo, Pérez Montilla Carlos, Mastrantonio Guido, Moscatelli Guillermo, Marson Maria Elena, and Prospitti Anabela

Subjects
Fetus, Pediatrics, medicine.medical_specialty, biology, business.industry, Toxoplasma gondii, General Medicine, biology.organism_classification, medicine.disease, Congenital toxoplasmosis, Toxoplasmosis, Sulfadiazine, Pyrimethamine, parasitic diseases, Medicine, business, Pediatric pharmacology, medicine.drug
Abstract

Infection with Toxoplasma gondii, is one of the most widespread zoonoses in the world. Congenital toxoplasmosis (CT) is particularly risky due to its fetal complications...

Published
2021

32. Acquired Syphilis by Nonsexual Contact in Childhood

Author

Moscatelli, Guillermo, primary, Moroni, Samanta, additional, García Bournissen, Facundo, additional, Falk, Nicolás, additional, Destito, Alejandra, additional, González, Nicolás, additional, Ballering, Griselda, additional, D’Amico, Indira, additional, García, Luciana, additional, and Altcheh, Jaime, additional

Published
2021
Full Text
View/download PDF

39. Congenital syphilis in Argentina: Experience in a pediatric hospital

Author

Garcia, Luciana Noemí, primary, Destito Solján, Alejandra, additional, Moroni, Samanta, additional, Falk, Nicolas, additional, Gonzalez, Nicolás, additional, Moscatelli, Guillermo, additional, Ballering, Griselda, additional, García Bournissen, Facundo, additional, and Altcheh, Jaime M., additional

Published
2021
Full Text
View/download PDF

41. Congenital chagas disease: Development and assessment of a specific IgM capture-based assay for diagnosis of transmission

Author

Peverengo, Luz María, primary, Rodeles, Luz María, additional, Maldonado, Camila, additional, Ballering, Griselda, additional, Pujato, Nazarena, additional, D’Amico, Indira, additional, Vicco, Miguel Hernán, additional, Garcia, Luciana, additional, Jurado, Laura, additional, Altcheh, Jaime, additional, and Marcipar, Iván, additional

Published
2021
Full Text
View/download PDF

47. Multilocus sequence typing of Treponema pallidum pallidumin children with acquired syphilis by nonsexual contact

Author

Garcia, Luciana N, Morando, Nicolás, Otero, Adrián V, Moroni, Samanta, Moscatelli, Guillermo F, Gonzalez, Nicolás, D Slojan, Alejandra, Lascano, Fernanda, Ballering, Griselda, Pando, Maria A, and Altcheh, Jaime M

Abstract

Background:There are scarce data of Treponema pallidumsubsp. pallidum(TPA) characterization in children with syphilis. Nonsexually acquired transmission (NSAT) of TPA is possible in infants through close contact. Methods:A descriptive study in five families with NSAT of syphilis was conducted. Polymerase chain reaction detection of TPA in pediatric index cases (n = 6) and their relatives (n = 44) were conducted followed by multilocus sequence typing (MLST). Results:TPA was detected in swab samples in 16 cases and 12 were characterized by MLST. Nichols lineage was identified in two of five families and SS14-lineage in three of five. In four families, MLST profiles linked index cases to relatives. Conclusion:This is the first report of TPA characterization in children infected by NSAT.

Published
2022
Full Text
View/download PDF

48. Review of pharmacological options for the treatment of Chagas disease.

Author

Lascano, Fernanda, García Bournissen, Facundo, and Altcheh, Jaime

Subjects
CHAGAS' disease, DRUG therapy, THERAPEUTICS, DRUG development, CHILDBEARING age
Abstract

Chagas disease (CD) is a worldwide problem, with over 8 million people infected in both rural and urban areas. CD was first described over a century ago, but only two drugs are currently available for CD treatment: benznidazole (BZN) and nifurtimox (NF). Treating CD‐infected patients, especially children and women of reproductive age, is vital in order to prevent long‐term sequelae, such as heart and gastrointestinal dysfunction, but this aim is still far from being accomplished. Currently, the strongest data to support benefit–risk considerations come from trials in children. Treatment response biomarkers need further development as serology is being questioned as the best method to assess treatment response. This article is a narrative review on the pharmacology of drugs for CD, particularly BZN and NF. Data on drug biopharmaceutical characteristics, safety and efficacy of both drugs are summarized from a clinical perspective. Current data on alternative compounds under evaluation for CD treatment, and new possible treatment response biomarkers are also discussed. Early diagnosis and treatment of CD, especially in paediatric patients, is vital for an effective and safe use of the available drugs (i.e. BZN and NF). New biomarkers for CD are urgently needed for the diagnosis and evaluation of treatment efficacy, and to guide efforts from academia and pharmaceutical companies to accelerate the process of new drug development. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results